Navigation Links
Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
Date:8/5/2008

SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, will announce financial results for its second quarter ended June 30, 2008, on Thursday, August 7, 2008, after the markets close. The announcement will be followed by a live webcast and conference call at 2:00 p.m. Pacific Time.

Orexigen management will host the call and webcast to discuss results for the second quarter ended June 30, 2008, and recent business highlights. The live call may be accessed by phone by calling (800) 860-2442 (domestic) or (412) 858-4600 (international). The webcast can be accessed live on the investor relations section of the Company's Web site at http://www.orexigen.com and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase III clinical trials, and Empatic(TM), which is in the later stages of Phase II clinical development. Both product candidates take advantage of the Company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
2. IBC Life Sciences Kicks Off the 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress in Boston, Massachusetts
3. VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress
4. CV Therapeutics Reports 2008 Second Quarter Financial Results
5. Horizon Therapeutics Announces Corporate Relocation to the Chicago Area
6. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
7. Cardinal Health, Prime Therapeutics Sign Primary Distribution Agreement
8. United Therapeutics Reports Second Quarter 2008 Financial Results
9. Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent
10. Silence Therapeutics Patent Update
11. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... PHILADELPHIA , June 28, 2017 ... Pediatrics at Georgetown University School of Medicine, and Founder, ... author of a study that has helped clarify the ... disease (PD) and other neurodegenerative diseases. Denise Barbut ... of Enterin Inc. was senior co-author of the study. ...
(Date:6/28/2017)... 2017 (PRWEB) , ... June ... ... of Siemens’ STAR-CCM+® software for multiphysics computational fluid dynamics (CFD) simulation and ... exploration and optimization. STAR-CCM+ version 12.04 introduces Design Manager, allowing users to ...
(Date:6/27/2017)... ... 2017 , ... Brain State Technologies, a leading neurotechnology company, ... 15th to fund production of the new B2v2 wearable brainwave balancing headband. Over ... more than 150% in a little over a week. , Utilizing Brain State’s ...
(Date:6/27/2017)... ... June 27, 2017 , ... DuPont Pioneer (DuPont) and ERS ... the ERS patent portfolio covering CRISPR-Cas genome editing technology for all agricultural uses ... (IP) of the CRISPR-Cas technology from co-inventor and co-owner Emmanuelle Charpentier, Ph.D. ...
Breaking Biology Technology:
(Date:6/14/2017)... , June 15, 2017  IBM (NYSE: IBM ) is ... tech event dedicated to developing collaboration between startups and global ... June 15-17. During the event, nine startups will showcase the ... in various industries. France ... international market, with a 30 percent increase in the number ...
(Date:5/16/2017)... May 16, 2017   Bridge Patient Portal ... and MD EMR Systems , an electronic ... for GE, have established a partnership to build ... and the GE Centricity™ products, including Centricity Practice ... These new integrations will allow healthcare ...
(Date:4/19/2017)... April 19, 2017 The global ... landscape is marked by the presence of several large ... held by five major players - 3M Cogent, NEC ... accounted for nearly 61% of the global military biometric ... in the global military biometrics market boast global presence, ...
Breaking Biology News(10 mins):